Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

CD19 chimeric antigen receptor (CAR) T cells can induce prolonged remissions and potentially cure a significant proportion of patients with relapsed/refractory large B-cell lymphomas. However, some patients may die of causes unrelated to lymphoma after CAR T-cell therapy. To date, little is known ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemoine, Jean, Bachy, Emmanuel, Cartron, Guillaume, Beauvais, David, Gastinne, Thomas, Di Blasi, Roberta, Rubio, Marie-Thérèse, Guidez, Stéphanie, Mohty, Mohamad, Casasnovas, Rene-Olivier, Joris, Magalie, Castilla-Llorente, Cristina, Haioun, Corinne, Hermine, Olivier, Loschi, Michael, Carras, Sylvain, Bories, Pierre, Fradon, Tom, Herbaux, Charles, Sesques, Pierre, Le Gouill, Steven, Morschhauser, Franck, Thieblemont, Catherine, Houot, Roch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641092/
https://www.ncbi.nlm.nih.gov/pubmed/37672383
http://dx.doi.org/10.1182/bloodadvances.2023010624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641092/
https://www.ncbi.nlm.nih.gov/pubmed/37672383
http://dx.doi.org/10.1182/bloodadvances.2023010624

Ejemplares similares